Elan Corp PLC (ELN)
7.07USD
9 Feb 2010
$0.10 (+1.43%)
$7.07
--
$7.15
$6.95
2,730,061
2,157,575
$8.59
$4.61
ELN
About
Overall
| Beta: | 0.93 |
| Market Cap (Mil.): | $4,127.05 |
| Shares Outstanding (Mil.): | 583.74 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| ELN | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 69.30 | 1.96 | 3.76 |
| EPS (TTM): | 114.87 | -- | -- |
| ROI: | 3.59 | 0.92 | 2.30 |
| ROE: | 62.31 | 1.27 | 2.82 |
CORRECTED - UPDATE 1-Elan expects rare operating profit in 2010
DUBLIN, Feb 10 (Reuters) - Irish drug maker Elan on Wednesday reported a loss of 10 cents on fourth quarter earnings per share, at the lower end of analyst expectations, but said it should make an operating profit in 2010 for the first time in years.
STOCKS NEWS EUROPE-Shares seen gaining for 3rd day
European stock index futures point to a higher open for equities, mirroring gains on Wall Street and in Asia, with hopes of a rescue package for Greece seen improving investor sentiment.
Biogen 4th-qtr profit up, outlook tops estimates
BOSTON (Reuters) - Biogen Idec Inc said on Tuesday its fourth-quarter earnings rose nearly 48 percent, driven by increased sales of its multiple sclerosis drugs and lower expenses.
UPDATE 3-Biogen 4th-qtr profit up, outlook tops estimates
* Shares up 1.8 percent in mid-morning trading. (Adds share reaction, company comment, rewrites throughout)
STOCKS NEWS EUROPE-Sanofi-Aventis, Peugeot in focus on Wed
FY Sanofi-Aventis
U.S. warns of risk rise with more Tysabri infusions
WASHINGTON (Reuters) - The risk of a potentially fatal brain disorder with Biogen Idec Inc's multiple sclerosis drug Tysabri increases as patients receive more infusions, U.S. health officials warned on Friday.
UPDATE 2-US warns of risk rise with more Tysabri infusions
* Biogen shares down slightly, Elan shares flat (Adds Biogen, FDA comments, updates share movement)
CORRECTED - UPDATE 3-Icahn seeks to nominate 3 to Biogen board
(Corrects sixth paragraph to show Richard Young was not nominated by Icahn last year)
Competitors
| Price | Change | |
|---|---|---|
| Biogen Idec Inc. (BIIB.OQ) | $54.09 | +1.25 |
| Merck KGaA (MRCG.DE) | €63.10 | +0.10 |
| Pfizer Inc. (PFE.N) | $17.88 | +0.04 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | ₪21,280.00 | -70.00 |
| Sanofi-Aventis SA (SASY.PA) | €53.03 | +0.37 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
